Transplantation and Cellular Therapy最新文献

{"title":"CD34+ Chimerism and Flow Cytometry Measurable Residual Disease are Independent Predictors of Relapse After Allogeneic Stem Cell Transplantation for AML","authors":"Michael D. Ashby, Elise Wallach, Michael Swain, Lisa Kechagias, Malgorzata Gorniak, Susan Morgan, Shaun Fleming, Sushrut Patil, Shu Min Wong, Shafqat Inam, Andrew Spencer, David J. Curtis","doi":"10.1016/j.jtct.2026.05.037","DOIUrl":"10.1016/j.jtct.2026.05.037","url":null,"abstract":"","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":"32 10","pages":"Pages 1242.e1-1242.e4"},"PeriodicalIF":4.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148057187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brexucabtagene Autoleucel in the Outpatient Setting: A Single-Institution Experience","authors":"Grace Johnson Mercadante, Phavina Akhom, Nur Ali, Brittney Baer, Eden Biltibo, Bhagirathbhai Dholaria, Brian Hoeynck, Andrew Jallouk, Reena Jayani, Salyka Sengsayadeth, James Jerkins, Adetola Kassim, Nancy Long, David Morgan, Vivek Patel, Bipin Savani, Olalekan Oluwole, Shakthi Bhaskar","doi":"10.1016/j.jtct.2026.05.041","DOIUrl":"10.1016/j.jtct.2026.05.041","url":null,"abstract":"","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":"32 10","pages":"Pages 1244.e1-1244.e4"},"PeriodicalIF":4.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148164643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toward a Standardized Definition of Reduced-Dose Post-transplant Cyclophosphamide in Allogeneic Hematopoietic Cell Transplantation","authors":"Nihar Desai, Jonas Mattsson","doi":"10.1016/j.jtct.2026.05.024","DOIUrl":"10.1016/j.jtct.2026.05.024","url":null,"abstract":"","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":"32 10","pages":"Pages 1188.e1-1188.e3"},"PeriodicalIF":4.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148164730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addition of High-Dose Cytarabine to Fludarabine, Busulfan, and Melphalan Conditioning for Cord Blood Transplantation in Adult Acute Myeloid Leukemia","authors":"Kyosuke Yamaguchi,&nbsp;Otoya Watanabe,&nbsp;Takashi Mitsuki,&nbsp;Kosei Kageyama,&nbsp;Daisuke Kaji,&nbsp;Yuki Taya,&nbsp;Aya Nishida,&nbsp;Kazuya Ishiwata,&nbsp;Shinsuke Takagi,&nbsp;Hisashi Yamamoto,&nbsp;Go Yamamoto,&nbsp;Yuki Asano-Mori,&nbsp;Atsushi Wake,&nbsp;Naoyuki Uchida,&nbsp;Shuichi Taniguchi","doi":"10.1016/j.jtct.2026.05.038","DOIUrl":"10.1016/j.jtct.2026.05.038","url":null,"abstract":"<div><div>The clinical benefit of adding high-dose cytarabine (HDCA) to fludarabine (FLU), busulfan (BU), and melphalan (MEL)–based conditioning for cord blood transplantation (CBT) in acute myeloid leukemia (AML) remains unclear. We aimed to investigate the safety and efficacy of HDCA in this setting. We retrospectively analyzed 300 patients with adult AML who underwent first CBT between 2010 and 2019 using FLU (180 mg/m²), BU (12.8 mg/kg), and MEL (80 mg/m²). To ensure uniformity of conditioning intensity, patients receiving cytarabine at doses other than 8000 mg/m² were excluded. Among them, 116 patients received HDCA (total 8000 mg/m²) during conditioning (HDCA group), whereas 77 received FLU/BU/MEL alone (non-HDCA group). Overall survival, nonrelapse mortality (NRM), relapse incidence, and transplant-related complications were evaluated. The median follow-up period was 316 (range, 3-3508) days. Patients in the HDCA group were more likely to be aged ≤55 years, have a performance status (PS) of 0-1, and receive tacrolimus alone for graft-versus-host disease prophylaxis than patients in the non-HDCA group. The 1-year OS rate was significantly higher in the HDCA group than in the non-HDCA group (64% versus 46%, <em>P</em> = .019), whereas the 1-year NRM (27% versus 39%) and relapse incidence (12% versus 17%) rates did not significantly differ between the two groups. However, after adjustment for baseline imbalances using propensity score matching, no statistically significant differences in OS, NRM, or relapse were observed between the groups. Rates of neutrophil engraftment, infections, and graft-versus-host disease were comparable between groups. Multivariate analysis identified age ≥56 years and PS ≥2 as independent adverse prognostic factors for overall survival. Among patients aged ≤55 years, omission of HDCA was independently associated with a higher risk of relapse. HDCA intensification of FLU/BU/MEL conditioning appears feasible without increasing transplant-related toxicity. Although an improvement in overall survival was observed in unadjusted analyses, no significant benefit was confirmed after adjustment for baseline imbalances. The potential reduction in relapse among younger patients should be considered exploratory. Further prospective studies incorporating molecular risk stratification are warranted.</div></div>","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":"32 10","pages":"Pages 1305.e1-1305.e11"},"PeriodicalIF":4.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148057205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes and Safety of CAR-T Cell Therapy in B-NHL Patients With Reduced Left Ventricular Ejection Fraction","authors":"Alexandra E. Rojek,&nbsp;Jia Guo,&nbsp;Justin Kline,&nbsp;Satyajit Kosuri,&nbsp;Michael R. Bishop,&nbsp;Jeanne DeCara,&nbsp;Peter A. Riedell","doi":"10.1016/j.jtct.2026.05.021","DOIUrl":"10.1016/j.jtct.2026.05.021","url":null,"abstract":"","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":"32 10","pages":"Pages 1240.e1-1240.e5"},"PeriodicalIF":4.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148102032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"T-Cell Lymphoma Associated With CAR-T Cell Therapy: A Bayesian Disproportionality Analysis of a National Database","authors":"Connor Frey","doi":"10.1016/j.jtct.2026.06.016","DOIUrl":"10.1016/j.jtct.2026.06.016","url":null,"abstract":"","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":"32 10","pages":"Pages 1245.e1-1245.e4"},"PeriodicalIF":4.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148228391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Hematopoietic Cell Transplantation in Patients with Plasmablastic Lymphoma","authors":"Taha Al-Juhaishi,&nbsp;Kwang Woo Ahn,&nbsp;Tiening Chen,&nbsp;Krina K. Patel,&nbsp;Jinalben Patel,&nbsp;Alex F. Herrera,&nbsp;Cameron J. Turtle,&nbsp;J. Douglas Rizzo,&nbsp;Farhad Khimani,&nbsp;Farrukh T. Awan,&nbsp;Fernando Gibran-Nunes,&nbsp;Gulrayz Ahmed,&nbsp;John Baird,&nbsp;Lazaros J. Lekakis,&nbsp;Mazyar Shadman,&nbsp;Mona Shafey,&nbsp;Peter A. Reidell,&nbsp;Reid W. Merryman,&nbsp;Mehdi Hamadani,&nbsp;Sairah Ahmed","doi":"10.1016/j.jtct.2026.05.030","DOIUrl":"10.1016/j.jtct.2026.05.030","url":null,"abstract":"<div><div>Plasmablastic lymphoma (PBL) is a rare and aggressive type of non-Hodgkin lymphoma with biological features that overlap between B-cell lymphoma and plasma cell neoplasm. There is currently no established standard treatment. However, intensive combination regimens, such as EPOCH, are recommended. There is a paucity of data regarding outcomes of hematopoietic cell transplantation (HCT) in this disease. Herein, we analyze data of patients with PBL who received autologous (autoHCT) or allogeneic (alloHCT) transplants using the Center for International Marrow and Transplant Research (CIBMTR) Registry. Between 2015 and 2024, a total of 186 and 31 patients underwent autoHCT and alloHCT, respectively, and met eligibility for the study. In the autoHCT group, 3-year overall survival (OS) was 75.5% (95% confidence interval [CI]: 68.3%–82.1%] and 3-year PFS was 60.6% (95% CI: 52.4%–68.5%], whereas 3-year NRM was 6.2% (95% CI: 2.9%–10.6%]. Outcomes of patients who received autoHCT after only 1 line of therapy were significantly better, with 3-year progression-free survival (PFS) at 74.7% (95% CI: 61%–85.7%] compared with 54% (95% CI: 39.9%–67.8%) in patients who received more than 1 line of therapy prior to transplantation (<em>P</em> = .046). In the alloHCT group, 3-year OS was 37.2% (95% CI: 19%–57.5%), 3-year PFS was 33.3% (95% CI: 16.3%–53.3%), and 3-year graft-versus-host disease–free/relapse-free survival was 20.8% (95% CI: 7.9%–37.8%), whereas 3-year nonrelapse mortality was 23.3% (95% CI: 8%–43.5%) and 3-year relapse risk was 43.3% (95% CI: 26%–61.6%). Relapse risk appears to plateau at approximately 1 year, suggesting the potential for curative outcomes in this disease. Overall, both autoHCT and alloHCT have demonstrated the potential to achieve prolonged survival in this aggressive lymphoma. However, early implementation of autoHCT following first-line therapy was associated with the most favorable outcomes.</div></div>","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":"32 10","pages":"Pages 1350.e1-1350.e11"},"PeriodicalIF":4.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148006797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chimeric Antigen Receptor-T Cells Fate after Infusion: Cellular Kinetics and Molecular Monitoring","authors":"Luisa Anelli,&nbsp;Cosimo Cumbo,&nbsp;Angela Minervini,&nbsp;Antonella Zagaria,&nbsp;Nicoletta Coccaro,&nbsp;Francesco Tarantini,&nbsp;Giuseppina Tota,&nbsp;Maria Rosa Conserva,&nbsp;Immacolata Redavid,&nbsp;Crescenzio Francesco Minervini,&nbsp;Elisa Parciante,&nbsp;Anna Mestice,&nbsp;Mario Delia,&nbsp;Giorgina Specchia,&nbsp;Pellegrino Musto,&nbsp;Francesco Albano","doi":"10.1016/j.jtct.2026.06.041","DOIUrl":"10.1016/j.jtct.2026.06.041","url":null,"abstract":"<div><div>Chimeric antigen receptor (CAR) T cells are considered human gene therapy products in which T lymphocytes are genetically modified to recognize a specific target antigen for therapeutic purposes. CAR-T cell therapy has shown particular success in the treatment of hematological neoplasms and, to date, the FDA has approved six commercial products for the treatment of relapsed/refractory B-cell malignancies. Because CAR-T cell therapy is associated with considerable toxicities, mainly cytokine release syndrome and neurological toxicity, it is reserved for patients with advanced-stage disease who have not responded to previous therapies and have no other treatment options. However, the efficacy of CAR-T cell therapy is highly variable, and approximately 30% to 50% of treated patients experience relapse after administration. Several variables, including the type of CAR construct, manufacturing procedure, infusion volume, quality of the manipulated T cells, and the patient’s tumor burden, may influence the fate and efficacy of CAR-T cells. In this review, specific attention is focused on molecular monitoring after infusion and on the potential occurrence of uncontrolled events, such as insertional mutagenesis, clonal T-cell expansion, or the onset of secondary T-cell lymphomas.</div></div>","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":"32 10","pages":"Pages 1212-1222"},"PeriodicalIF":4.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148319314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ASTCT Consensus Grading for Toxicities after Immune Effector Cell Therapy","authors":"Miguel-Angel Perales,&nbsp;Jorg Dietrich,&nbsp;Juliane Gust,&nbsp;Bianca Santomasso,&nbsp;Kai Rejeski,&nbsp;Doris Hansen,&nbsp;Nirali N. Shah,&nbsp;Jesus Berdeja,&nbsp;Michael Bishop,&nbsp;Eric Bleickardt,&nbsp;Jennifer Brudno,&nbsp;Saurabh Dahiya,&nbsp;Noelle Frey,&nbsp;Matthew J. Frigault,&nbsp;Rebecca Gardner,&nbsp;Armin Ghobadi,&nbsp;Stephan Grupp,&nbsp;Mehdi Hamadani,&nbsp;Caron Jacobson,&nbsp;Michael D. Jain,&nbsp;Frederick L. Locke","doi":"10.1016/j.jtct.2026.05.020","DOIUrl":"10.1016/j.jtct.2026.05.020","url":null,"abstract":"<div><div>In 2019, the American Society for Transplantation and Cellular Therapy (ASTCT) developed consensus definitions and grading criteria for the common immune effector cell (IEC)-associated toxicities of cytokine release syndrome (CRS) and IEC-associated neurotoxicity syndrome (ICANS). These grading scales were widely adopted by clinicians, investigators, and sponsors, allowing a clearer understanding of outcomes across clinical trials and a uniform basis to inform treatment algorithms. Since then, other IEC class effects, such as IEC-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) and non-ICANS attributable neurotoxicity, have been recognized. ASTCT convened experts for 2 tasks. First, to consider updating the previously published ASTCT grading criteria for CRS, ICANS, and IEC-HS. Second, to consider existing definitions and grading criteria, and/or create consensus criteria for emerging toxicities, including immune effector cell-associated hematotoxicity; non-ICANS neurological toxicities such as parkinsonism, cranial nerve palsies, and polyneuropathies; IEC-associated enterocolitis; tumor inflammation-associated neurotoxicity; and on-target, off-tumor toxicities. These updated consensus toxicity definitions and grading criteria can facilitate comparisons of toxicities of IEC and T-cell engager therapy across clinical trials and in real-world settings, as well as aid clinicians in better characterizing the severity of toxicity that can ultimately be tied to management guidelines.</div></div>","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":"32 10","pages":"Pages 1189-1211"},"PeriodicalIF":4.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148913523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Masthead (Purpose and Scope)","authors":"","doi":"10.1016/S2666-6367(26)00733-5","DOIUrl":"10.1016/S2666-6367(26)00733-5","url":null,"abstract":"","PeriodicalId":23283,"journal":{"name":"Transplantation and Cellular Therapy","volume":"32 10","pages":"Pages A1-A2"},"PeriodicalIF":4.7,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149124627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}